Lung Cancer Archives | VJOncology

The Lung Cancer Channel on VJOncology is supported by Janssen Oncology (a pharmaceutical company of Johnson & Johnson), Takeda and AstraZeneca. These supporters have no influence over the production of the content.

View overview page

Molecular testing for adenocarcinoma and squamous cell lung cancer

Sonam Puri • 15 Jun 2021

Osimertinib + ipilimumab in EGFR-mutated NSCLC

Sonam Puri • 15 Jun 2021

Surgical outcomes from the Phase III CheckMate 816 trial

Jonathan Spicer • 11 Jun 2021

Surgical endpoints are needed in lung cancer trials of neoadjuvant therapy

Jonathan Spicer • 11 Jun 2021

NSCLC highlights from ASCO 2021

Heather A. Wakelee • 9 Jun 2021

Real-world molecular characterization of SCLC subtypes

Sonam Puri • 15 Jun 2021

Disease-free survival in IMpower010 trial: adjuvant atezolizumab in NSCLC

Sanjay Popat • 11 Jun 2021

New therapies for NSCLC

Heather A. Wakelee • 9 Jun 2021

Activity of EGFR TKIs in patients with NSCLC with uncommon EGFR mutations

Sanjay Popat • 11 Jun 2021

Lung cancer trial updates at ASCO 2021

Benjamin Besse • 7 Jun 2021

Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer

Heather A. Wakelee • 9 Jun 2021

The future of NSCLC treatment

Benjamin Besse • 7 Jun 2021

Bispecific antibodies in lung cancer

Benjamin Besse • 7 Jun 2021

Updated overall efficacy and safety of selpercatinib in patients with RET fusion+ NSCLC

Benjamin Besse • 7 Jun 2021

Phase I/II trial of zenocutuzumab for tumors with NRG1 fusions

Alison M. Schram • 4 Jun 2021

Targeted therapy versus standards of care in metastatic NSCLC

Benjamin Besse • 7 Jun 2021

1
2
3
Next